Neurodegenerative diseases (NDs) are characterized by disorders with progressive deterioration of the structure and/or function of neurons. Genetic mutations can lead to many NDs. Nevertheless, neurodegeneration can also take place due to several biological processes. The pathogenesis of several NDs including Alzheimer's (AD), Parkinson's (PD), and Huntington's (HD) diseases are associated with oxidative stress (OS). In order to maintain the normal functions of neurons, lower levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) are important, since their increased levels can cause neuronal cell death. It has been found that OS-mediated neurodegeneration involves a number of events including mitochondrial dysfunction, Ca overload, and excitotoxicity. A growing number of studies are suggesting the benefit of using polyphenols for the treatment of neurodegenerative disorders. Indeed, in order to treat most of the NDs, synthetic drugs are extensively used which are found to exert side effects in the course of the treatment. There is mounting evidence that researchers have identified several naturally-occurring chemical compounds in plants, which are used for the management of NDs. Overall, polyphenolic phytochemicals are safer in nature and have negligible side effects. In this article, we have focused on the potential efficacy of polyphenols such as epigallocatechin-3-gallate, curcumin, resveratrol, quercetin and methylated polyphenols berberine against the most common neurodegenerative disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2020.173412DOI Listing

Publication Analysis

Top Keywords

neurodegenerative disorders
8
side effects
8
nds
5
neuroprotective role
4
polyphenols
4
role polyphenols
4
polyphenols oxidative
4
oxidative stress-mediated
4
stress-mediated neurodegeneration
4
neurodegeneration neurodegenerative
4

Similar Publications

Background: Therapeutic antibodies for the treatment of neurological disease show great potential, but their applications are rather limited due to limited brain exposure. The most well-studied approach to enhance brain influx of protein therapeutics, is receptor-mediated transcytosis (RMT) by targeting nutrient receptors to shuttle protein therapeutics over the blood-brain barrier (BBB) along with their endogenous cargos. While higher brain exposure is achieved with RMT, the timeframe is short due to rather fast brain clearance.

View Article and Find Full Text PDF

Previous studies have suggested that systemic viral infections may increase risks of dementia. Whether this holds true for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infections is unknown. Determining this is important for anticipating the potential future incidence of dementia.

View Article and Find Full Text PDF

Toward a biological definition of neuronal and glial synucleinopathies.

Nat Med

January 2025

Department of Neurology & Neurological Sciences, Stanford Movement Disorders Center, Stanford University, Stanford, CA, USA.

Cerebral accumulation of alpha-synuclein (αSyn) aggregates is the hallmark event in a group of neurodegenerative diseases-collectively called synucleinopathies-which include Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Currently, these are diagnosed by their clinical symptoms and definitively confirmed postmortem by the presence of αSyn deposits in the brain. Here, we summarize the drawbacks of the current clinical definition of synucleinopathies and outline the rationale for moving toward an earlier, biology-anchored definition of these disorders, with or without the presence of clinical symptoms.

View Article and Find Full Text PDF

The prevalence of Alzheimer's disease (AD) is increasing as society ages. The details of AD pathogenesis have not been fully elucidated, and a comprehensive gene expression analysis of the process leading up to the onset of AD would be helpful for understanding the mechanism. We performed an RNA sequencing analysis on a cohort of 1227 Japanese blood samples, representing 424 AD patients, 543 individuals with mild cognitive impairment (MCI), and 260 cognitively normal (CN) individuals.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!